IC
ANIK icon

Inscription Capital’s Anika Therapeutics ANIK Stock Holding History

Inscription Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Buy
13,750
+3,734
+37% +$55.3K 0.02% 709
2026
Q1 		$145K Sell
10,016
-2,650
-21% -$30.8K 0.02% 651
2025
Q4 		$122K Buy
+12,666
New +$121K 0.01% 642

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Inscription Capital's ANIK Position: Q2 2026 in Review

Inscription Capital increased its Anika Therapeutics (ANIK) stake by 37% in Q2 2026, buying an estimated $55.3K and bringing the position to 13,750 shares worth $201K. The position accounts for 0.02% of the portfolio, ranked #709.

Inscription Capital first reported a position in ANIK in Q4 2025 and has held it in 3 quarters since. 134 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Inscription Capital held 13,750 shares of Anika Therapeutics worth $201K as of Q2 2026.
  • Inscription Capital bought 3,734 Anika Therapeutics shares in Q2 2026, an estimated $55.3K.
  • Anika Therapeutics made up 0.02% of Inscription Capital's portfolio in Q2 2026, its #709 holding.
  • Inscription Capital first reported a position in Anika Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 134 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.